Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease
Main finding · 2-point MACEResult — go to the resultHazard ratio 0.696 95 % CI 0.626–0.774Authors' conclusion
Persistence with OW GLP-1 RA therapy was associated with significantly lower MACE risk among patients with T2DM and ASCVD in a real-world setting.
Study context
- Population
- Patients with T2D and atherosclerotic cardiovascular disease (ASCVD) who initiated OW GLP-1 RAs between 1/1/2018–11/30/2022, Optum Research Database
- Participants
- 18,849 vs 10,667
- Exposure
- Persistent vs non-persistent OW GLP-1 RA therapy
- Persistentn = 18,849
- Non-persistentn = 10,667reference
- Outcome
- 2-point major adverse cardiovascular events (MACE)
Methodological detailsadjusted time-varying Cox proportional hazards models
- Adjusted time-varying Cox proportional hazards models
Main finding
As reported in the abstract
Hazard ratio
0.696
95 % CI 0.626–0.774
P < 0.001
Persistentvs Non-persistent
HR 0.696 (95 % CI 0.626–0.774); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | P value | |
|---|---|---|---|
| Stroke | 0.668 (0.573–0.777) | P < 0.001 | |
| MI | 0.710 (0.621–0.813) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Duration of persistence
Follow-up duration
Original publication
Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Diabetes Res Clin Pract. Published 10 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →